Quality Level
assay
98%
form
powder
reaction suitability
reaction type: solution phase peptide synthesis
mp
192-195 °C (lit.)
application(s)
peptide synthesis
SMILES string
NCCCCCCC(O)=O
InChI
1S/C7H15NO2/c8-6-4-2-1-3-5-7(9)10/h1-6,8H2,(H,9,10)
InChI key
XDOLZJYETYVRKV-UHFFFAOYSA-N
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Is there any need for a TAFI(a) inhibitor as thrombolytic drug?
Ellen Vercauteren et al.
Thrombosis research, 130(4), 574-575 (2012-07-31)
V S De Serrano et al.
Biochemistry, 32(14), 3540-3548 (1993-04-13)
The involvement of specific aspartic acid (D) and glutamic acid (E) residues of the recombinant (r) kringle 2 (K2) domain of tissue-type plasminogen activator (tPA) in stabilizing its interaction with omega-amino acid ligands has been assessed by examination of these
V S De Serrano et al.
Biochemistry, 31(47), 11698-11706 (1992-12-01)
The properties of the cationic locus within the recombinant (r) kringle 2 domain (residues 180-261) of tissue-type plasminogen activator ([K2tPA]) that are responsible for stabilization of its interaction with the carboxylate moiety of omega-amino acid ligands have been assessed by
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 284637-1G | 04061826101261 |